Dyne Therapeutics is a clinical-stage biotechnology company developing targeted therapies for genetically driven neuromuscular diseases. The company utilizes its proprietary FORCE platform, which employs a transferrin receptor 1 (TfR1)-binding antibody fragment to deliver therapeutic payloads to muscle tissue and the central nervous system. Its product portfolio includes zeleciment rostudirsen (DYNE-251) for Duchenne muscular dystrophy and zeleciment basivarsen (DYNE-101) for myotonic dystrophy type 1, both of which are in global Phase 1/2 clinical trials. The company is also developing product candidates for facioscapulohumeral dystrophy and Pompe disease, with plans to expand into other rare skeletal muscle, cardiac, and metabolic muscle diseases. Dyne Therapeutics targets patients with high unmet need, utilizing payloads such as phosphorodiamidate morpholino oligomers, antisense oligonucleotides, and enzymes to address the genetic basis of these conditions.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage dyne-tx.com
Sector Healthcare IR page investors.dyne-tx.com/investor-resources/faqs
Tags
neuromuscular diseases, muscular dystrophy, rare diseases, oligonucleotide therapeutics, targeted drug delivery, genetic disorders, FORCE platform, zeleciment rostudirsen, DYNE-251, zeleciment basivarsen, DYNE-101
Press page —

Metrics

Valuation  
Market cap $ 3.151B
Market cap (USD) $ 3.151B
P/E -4.72
PEG —
P/BV 3.38
P/S —
P/OCF -5.58
P/FCF -5.54
Dividend yield —
Turnover / mcap —
Returns  
ROE -55.7%
ROI -39.8%
ROIC -31.3%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 21.5%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 67
Quality score -75.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Assets 1.187B 691.234M 165.082M 306.325M 425.663M 353.334M 16.436M
Net profit -446.214M -317.418M -235.937M -168.099M -149.291M -59.437M -14.859M
Free cash flow -405.127M -294.745M -188.887M -156.712M -123.181M -47.669M -13.481M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 19.56 23.56 13.3 11.59 11.89 21 0.47
Price performance 12m -0.17 0.77 0.15 -0.03 -0.43 — 0.16

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — 0.00 32.6M 30.5M 27.4M 24M 20.3M
Cash and deposits (USD) 14.6M 301M 201M 172M 122M 435M 893M
Right-of-use assets (USD) — 0.00 36.3M 32.5M 28.6M 24.6M 20.7M
Cash flow detail
Operating cash flow (USD) -11.8M -46.5M -120M -154M -188M -292M -403M
Purchases of property, plant and equipment (USD) -1.65M -1.16M -3.62M -3.07M -729,000 -2.38M -1.92M
Interest paid (cash effect) (USD) — — — — 0.00 0.00 -4.34M
Share-based compensation (USD) 26,000 6.59M 17.5M 15.2M 20M 45.9M 45.9M
Free cash flow (OCF - PPE - intangibles) (USD) -13.5M -47.7M -123M -157M -189M -295M -405M
Income detail
Research and development expense (USD) 11M 45.2M 121M 143M 211M 281M 398M
↳ 5y CAGR +91.1% +54.5%
Total comprehensive income (USD) -14.9M -59.5M -150M -168M -235M -317M -446M
Comprehensive income to owners (USD) -14.9M -59.5M -150M -168M -235M -317M -446M
Reported Mar 4, 2021 Mar 10, 2022 Mar 10, 2022 Mar 2, 2023 Mar 2, 2026 Mar 2, 2026 Mar 2, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 5, 2026

Download PDF

  • Biologics License Application (BLA) for z-rostudirsen in exon 51 Duchenne muscular dystrophy (DMD) under priority review by FDA; PDUFA target action date of January 21, 2027 -

  • Additional one-year clinical data from Phase 1/2 ACHIEVE trial of z-basivarsen for myotonic dystrophy type 1 (DM1) presented at WMS and AANEM continued to support improvement at 6 months in video hand opening time (vHOT) as an early indicator of clinical benefit -

  • Topline data from ACHIEVE registrational expansion cohort (REC) planned for Q1 2027 -

  • Preclinical data presented at NMSG support the ongoing development of four investigational therapies for DMD amenable to skipping of exons 44, 45, 53, or 55 -

WALTHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today reported financial results for the third quarter of 2026 and recent business highlights.

“As we work toward potential commercialization, we are investing across multiple programs with the goal of unlocking the full value of our FORCETM platform,” said John Cox, president and chief executive officer of Dyne. “This includes preparations for the potential U.S. launch of z-rostudirsen for exon 51 DMD, if approved, and topline data from the registrational expansion cohort of the ACHIEVE trial for z-basivarsen in DM1, both expected in the first quarter of 2027. At the same time, we are advancing HARMONIA, the only Phase 3 clinical trial in DM1 currently enrolling participants and progressing four preclinical DMD programs that have the potential to expand our reach to over one third of individuals living with Duchenne.”

Zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD**(Duchenne muscular dystrophy)**

Key milestones for z-rostudirsen

  • Dyne’s BLA is under priority review by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date of January 21, 2027.

  • Dyne continues to expect a potential U.S. launch of z-rostudirsen in Q1 2027, assuming approval is received on the anticipated timeline.

  • The ongoing confirmatory Phase 3 FORZETTO trial of z-rostudirsen is intended to support conversion of Accelerated Approval, if granted, to traditional approval in the U.S. and to support ex-U.S. marketing applications.

  • In addition to z-rostudirsen, Dyne is advancing four development candidates (DYNE-244, DYNE-245, DYNE-253 and DYNE-255) for the potential treatment of DMD amenable to skipping of exons 44, 45, 53, and 55, respectively. Preclinical data supporting the ongoing development of these investigational therapies was recently presented at the 27th Annual Neuromuscular Study Group (NMSG) Scientific Meeting.

Zeleciment basivarsen (z-basivarsen, also known as DYNE-101) in DM1 (myotonic dystrophy type 1)

Additional one-year clinical data from Phase 1/2 ACHIEVE trial

  • Dyne presented additional one-year efficacy data from the multiple ascending dose (MAD) portion of the ongoing Phase 1/2 ACHIEVE clinical trial of z-basivarsen at the 31st Annual International Congress of the World Muscle Society (WMS) and the 2026 Annual Meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM).

  • Data from a pooled dose group of participants initially enrolled in the MAD portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus a matched natural history cohort across multiple measures at 12 months.

Key milestones for z-basivarsen

  • Topline data from the ACHIEVE REC are planned for Q1 2027 to support a potential BLA submission for U.S. Accelerated Approval in Q3 2027.

  • Dyne intends to use data from the REC and from the already enrolled participants in the MAD and ongoing long-term extension portions of the ACHIEVE trial to support this potential BLA submission.

  • Dyne expects a potential U.S. launch of z-basivarsen in H1 2028, assuming the FDA grants Priority Review and approval is received on the anticipated timeline.

  • The ongoing confirmatory Phase 3 HARMONIA trial of z-basivarsen is intended to support conversion of Accelerated Approval, if granted, to traditional approval in the U.S. and to support ex-U.S. marketing applications.

Third Quarter Financial Results

Cash position: Cash, cash equivalents and marketable securities were $1.134 billion as of September 30, 2026. The Company expects that its cash, cash equivalents and marketable securities as of September 30, 2026, will be sufficient to fund its operations into the second quarter of 2028.

Research and development (R&D) expenses: R&D expenses were $161.7 million for the three months ended September 30, 2026 compared to $97.2 million for the three months ended September 30, 2025. The increase in R&D expense was primarily due to increased manufacturing activity for z-rostudirsen and higher clinical trial costs related to conducting the ongoing FORZETTO and HARMONIA Phase 3 trials for z-rostudirsen and z-basivarsen, respectively.

General and administrative (G&A) expenses: G&A expenses were $35.3 million for the three months ended September 30, 2026 compared to $16.7 million for the three months ended September 30, 2025. The increase in G&A expenses was primarily due to preparation for the potential launch of z-rostudirsen, including an increase in headcount.

Net loss: Net loss for the three months ended September 30, 2026 was $193.6 million, or $1.06 per basic and diluted share. This compares with a net loss of $108.0 million, or $0.76 per basic and diluted share, for the three months ended September 30, 2025.

About Dyne Therapeutics

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding: Dyne’s strategy, future operations, prospects, projections and plans; objectives of management; the potential of the FORCE platform; the potential of zeleciment basivarsen (z-basivarsen, also known as DYNE-101), zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251), DYNE-244, DYNE-245, DYNE-253, DYNE-255 and DYNE-302; the anticipated timelines for initiating additional clinical trials, reporting data from clinical trials, submitting applications for marketing approval and launching commercially; the availability of an expedited approval pathway for z-basivarsen; expectations regarding the potential timing and likelihood of regulatory approval and commercial launch; the outcome of interactions with regulatory authorities; and the sufficiency of Dyne’s cash resources for the period anticipated, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” “will” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the initiation and completion of clinical trials; uncertainties as to the availability and timing of results from clinical trials; uncertainties as to the timing of and Dyne’s ability to enroll patients in clinical trials; whether results from preclinical studies and data from clinical trials will be predictive of the final results of the clinical trials or other trials; whether data from clinical trials will support submission for regulatory approvals; uncertainties as to the FDA’s and other regulatory authorities’ interpretation of the data from Dyne's clinical trials and acceptance of Dyne's clinical programs; the regulatory approval process for Dyne’s product candidates; whether Dyne’s cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses, debt service obligations and capital expenditure requirements; as well as the risks and uncertainties identified in Dyne’s filings with the Securities and Exchange Commission (SEC), including the company’s most recent Form 10-Q and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne’s views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne’s views as of any date subsequent to the date of this press release.

| Dyne Therapeutics, Inc. |

| Condensed Consolidated Statement of Operations |

| (in thousands, except share and per share data) |

| | Three Months Ended | |

| | September 30, | |

| | 2026 | | | 2025 | |

| Operating expenses: | | | | | |

| Research and development | $ | 161,744 | | | $ | 97,219 | |

| General and administrative | | 35,330 | | | | 16,673 | |

| Total operating expenses | | 197,074 | | | | 113,892 | |

| Loss from operations | | (197,074 | ) | | | (113,892 | ) |

| Other income, net | | 3,522 | | | | 5,851 | |

| Net loss | $ | (193,552 | ) | | $ | (108,041 | ) |

| Net loss per share, basic and diluted | $ | (1.06 | ) | | $ | (0.76 | ) |

| Weighted average common shares outstanding, basic and diluted | | 181,765,918 | | | | 141,810,881 | |

| Dyne Therapeutics, Inc. | |

| Condensed Consolidated Balance Sheet Data | |

| (in thousands) | |

| | | September 30, | | | December 31, | |

| | | 2026 | | | 2025 | |

| Assets | | | | | | |

| Cash, cash equivalents and marketable securities | | $ | 1,134,386 | | | $ | 1,110,562 | |

| Other assets | | | 100,416 | | | | 76,396 | |

| Total assets | | $ | 1,234,802 | | | $ | 1,186,958 | |

| Liabilities and Stockholders’ Equity | | | | | | |

| Liabilities | | | 303,869 | | | | 214,829 | |

| Stockholders' equity | | | 930,933 | | | | 972,129 | |

| Total liabilities and stockholders' equity | | $ | 1,234,802 | | | $ | 1,186,958 | |

October 22, 2026

Download PDF

WALTHAM, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 16 newly hired employees. The awards were made as an inducement material to the newly hired employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement equity awards consisted of non-statutory stock options to purchase up to an aggregate of 290,100 shares of Dyne’s common stock at a per share exercise price equal to the closing price of Dyne’s common stock on The Nasdaq Global Select Market on October 20, 2026, and restricted stock units with respect to an aggregate of 92,300 shares of Dyne’s common stock. The stock options have a ten-year term and are scheduled to vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s start date and the remainder vesting in 12 equal quarterly installments thereafter, subject to such employee’s continued service to Dyne through the applicable vesting dates. The restricted stock units are scheduled to vest over four years from the applicable employee’s start date in four equal annual installments, subject to such employee’s continued service to Dyne through the applicable vesting dates.

The inducement equity awards are subject to the terms and conditions of award agreements covering the grants and Dyne’s 2024 Inducement Stock Incentive Plan.

About Dyne Therapeutics

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.

September 29, 2026

Download PDF

  • Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus a matched natural history cohort across multiple measures at 12 months -

  • Data continued to support improvement at 6 months in video hand opening time (vHOT) as an early indicator of clinical benefit with z-basivarsen in DM1 -

  • Dyne continues to expect topline data in Q1 2027 from the ACHIEVE registrational expansion cohort (REC), with a primary endpoint of change from baseline in vHOT at 6 months, intended to support a potential submission for U.S. Accelerated Approval in Q3 2027 -

  • The mean baseline vHOT in the ACHIEVE REC is 8.3 seconds -

WALTHAM, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced additional one-year efficacy data from the MAD portion of its ongoing Phase 1/2 ACHIEVE clinical trial of zeleciment basivarsen (z-basivarsen, also known as DYNE-101) for DM1, showing functional improvement across multiple measures. These data are being presented at the 31st Annual International Congress of the World Muscle Society (WMS) being held September 29, 2026, through October 3, 2026, virtually and in Hiroshima, Japan, as well as the 2026 Annual Meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) being held September 29, 2026, through October 2, 2026, virtually and in Orlando, Florida.

“This week we are presenting data at 6 and 12 months from a larger pooled dose group of participants from ACHIEVE, which further support our confidence in the results we have previously presented from smaller individual dose cohorts,” said Doug Kerr, M.D., Ph.D., chief medical officer of Dyne. “In addition, for the first time, we are showing functional improvement across multiple measures compared to a matched natural history cohort, not just compared to placebo and compared to baseline. We attribute these results to the differentiated properties of our FORCE platform and z-basivarsen, which is designed to correct the core underlying splicing abnormalities in DM1 by delivering a targeted therapeutic payload to the nucleus in both muscle and the CNS. We aim to confirm these findings through both the ACHIEVE REC and the Phase 3 HARMONIA study, which is currently recruiting participants at over 35 active global sites.”

The analyses being presented at WMS and AANEM were designed to evaluate whether a larger treated group showed the same positive efficacy trends previously observed in a smaller cohort of participants receiving the registrational dose of 6.8 mg/kg Q8W (N=6). Data from a pooled dose group of participants (N=25-26) from the 3.4 mg/kg Q4W, 5.4 mg/kg Q8W and 6.8 mg/kg Q8W cohorts of the MAD portion of the ACHIEVE trial, including participants originally assigned to the placebo group (re-baselined to the visit prior to their first active dose), were assessed through 12 months of treatment.

The pooled dose group includes a mixture of dose exposures and does not reflect the effect of maintaining the registrational dose of 6.8 mg/kg for the entire treatment duration, as only 8 of 26 participants in the pooled dose group received the registrational dose for the full 12 months analyzed and most did not receive the registrational dose during this timeframe.

At 12 months, these data were compared to a cohort of participants (N=41-46) from the ongoing END-DM1 natural history study who were propensity-matched to the ACHIEVE pooled dose group.

The new results to be presented at WMS and AANEM include:

  • **Myotonia:**Sustained improvement from baseline in hand myotonia, as measured by vHOT. The pooled dose group had a mean baseline vHOT of 8.2 seconds, which decreased by 3.2 seconds at 6 months (standard deviation of change from baseline: 3.5 seconds). This is compared to an increase of 0.4 seconds in the placebo group from the ACHIEVE MAD at 6 months (N=14), representing a 3.6 second relative improvement. The change from baseline in vHOT at 6 months is the primary endpoint of the ACHIEVE REC, from which topline data are expected in Q1 2027 to support a potential Biologics License Application (BLA) submission for U.S. Accelerated Approval in Q3 2027.

  • **Function:**Sustained improvement from baseline in function, as assessed by the 5 times sit to stand (5xSTS) test and the 10-meter walk/run (10MWR) test. In the pooled dose group at 12 months, participants improved on 5xSTS by 1.2 seconds and on 10MWR by 0.3 seconds relative to baseline, showing a divergence from the matched natural history cohort on 10MWR. 5xSTS was not included in the END-DM1 natural history study, so no comparisons could be made. The change from baseline in 5xSTS at 12 months is the primary endpoint of the ongoing global Phase 3 HARMONIA clinical trial, which is intended to serve as a confirmatory trial for traditional approval in the U.S. and support ex-U.S. marketing applications.

  • Strength: Sustained improvement from baseline on muscle strength as assessed by the quantitative muscle testing (QMT) total score and the individual QMT hand grip score. In the pooled dose group at 12 months, participants improved on both QMT total and hand grip by 4.8% predicted relative to baseline, showing a divergence from the matched natural history cohort on both measures.

  • Patient Reported Outcomes: Sustained improvement from baseline in the Myotonic Dystrophy Health Index (MDHI) patient reported outcome measure, including in 6 subscales assessing central nervous system (CNS) disease manifestations (cognitive impairment, sleep disturbances, fatigue, communication, emotional issues and pain). In the pooled dose group at 12 months, participants improved on the MDHI total score by 25.2% relative to baseline, showing a divergence from an unmatched END-DM1 natural history cohort (N=410).

  • **Safety and Tolerability:**Updated safety and tolerability data from participants initially enrolled in the MAD portion of the ACHIEVE trial. Z-basivarsen continued to demonstrate a favorable safety profile, and no related serious treatment emergent adverse events were identified.1

These data will be presented in an oral presentation at WMS titled “Long-term functional improvement with zeleciment basivarsen in the Phase 1/2 ACHIEVE trial.” The slides for this presentation are now available in the Scientific Publications & Presentations section of Dyne's website. Additionally, these data will be presented in a poster presentation at AANEM titled “Zeleciment basivarsen targets the underlying cause of myotonic dystrophy type 1 to enable functional improvement in the Phase 1/2 ACHIEVE trial,” which will be available in the Scientific Publications & Presentations section of Dyne's website on Wednesday, September 30 at 6:15 p.m. ET.

Baseline vHOT of the ACHIEVE Registrational Expansion Cohort (REC)

The mean baseline value for vHOT of the 71 participants enrolled in the ACHIEVE REC is 8.3 seconds (standard deviation at baseline: 6.0 seconds). These baseline data remain blinded to treatment assignment. Topline data from the ACHIEVE REC, which is intended to support a potential application for U.S. Accelerated Approval, are planned for Q1 2027.

About the ACHIEVE Trial

ACHIEVE is a global, randomized, placebo-controlled, double-blind, Phase 1/2 clinical trial evaluating the safety, tolerability and efficacy of zeleciment basivarsen (z-basivarsen, also known as DYNE-101) in patients with myotonic dystrophy type 1 (DM1). The multiple ascending dose (MAD) portion of the study resulted in the selection of a registrational dose and regimen of 6.8 mg/kg z-basivarsen administered every eight weeks. A registrational expansion cohort to support potential regulatory submissions, including Accelerated Approval in the U.S., is fully enrolled. The primary endpoint for this cohort is the change from baseline in middle finger myotonia as measured by video hand opening time (vHOT) at 6 months, compared to placebo. For more information on the ACHIEVE trial, visit www.clinicaltrials.gov (NCT05481879) and euclinicaltrials.eu (EUCT2023-510353-42-00).

About zeleciment basivarsen (z-basivarsen, also known as DYNE-101)

Z-basivarsen is an investigational therapeutic being evaluated in the fully enrolled global Phase 1/2 ACHIEVE clinical trial and the global confirmatory Phase 3 HARMONIA clinical trial for people living with DM1. Z-basivarsen consists of an antisense oligonucleotide (ASO) conjugated to an antigen-binding fragment (Fab) that binds to the transferrin receptor 1 (TfR1) to enable delivery to muscle and the central nervous system. It is designed to deliver functional improvement in individuals living with DM1 by reducing toxic nuclear DMPK RNA to release splicing proteins and allow normal mRNA processing. Z-basivarsen has been granted Breakthrough Therapy, Orphan Drug and Fast Track designations by the U.S. Food and Drug Administration (FDA), as well as Orphan Drug designation from the European Medicines Agency (EMA) and the Ministry of Health, Labour and Welfare (MHLW) in Japan for the treatment of DM1.

About Myotonic Dystrophy Type 1 (DM1)

Myotonic dystrophy type 1 (DM1) is a rare, progressive, genetic neuromuscular disease with high morbidity and early mortality. DM1 affects ~40,000 people in the U.S. and ~55,000 people in the EU. The severity of symptoms and rate of progression vary. Symptoms can begin at any point in an affected person's life, depending on the DM1 subtype. Adult-onset DM1 symptoms typically appear between 20 to 40 years of age. DM1 is caused by mutations in the DMPK gene, leading to a widespread disruption of RNA splicing, known as spliceopathy, which drives the multi-system manifestations of the disease. People experience a broad spectrum of symptoms, including: muscle weakness throughout the body, myotonia or difficulty relaxing muscles, excessive daytime sleepiness, fatigue, dysregulated sleep, cognitive impairments, cardiac arrhythmias, respiratory issues and gastrointestinal dysfunction. Although the genetic cause of DM1 is well understood, there are currently no approved disease-modifying treatments for DM1.

About Dyne Therapeutics

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Dyne's strategy, future operations, prospects and plans, objectives of management, the potential of the FORCE platform, the clinical potential of zeleciment basivarsen (“z-basivarsen,” also known as DYNE-101) and its potential to mitigate central nervous system-related manifestations of myotonic dystrophy type 1, expectations regarding the timing and outcome of data from clinical trials, expectations regarding the timing and outcome of submissions to and interactions with global regulatory authorities, the availability of accelerated approval pathways for z-basivarsen, and the potential of video hand opening time to serve as an intermediate clinical endpoint for U.S. accelerated approval, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” ”might,” ”objective,” ”ongoing,” ”plan,” ”predict,” ”project,” ”potential,” ”should,” ”will” or ”would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and Dyne's ability to enroll patients in clinical trials; whether results from preclinical studies and initial data from early clinical trials will be predictive of the final results of the clinical trials or future trials; uncertainties as to the FDA's and other regulatory authorities' interpretation of the data from Dyne's clinical trials and acceptance of Dyne's clinical programs and the regulatory approval process; whether Dyne's cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Dyne's filings with the Securities and Exchange Commission (SEC), including the Company's most recent Form 10-Q and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne's views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne's views as of any date subsequent to the date of this press release.

  1. Z-basivarsen safety data as of April 20, 2026.

Prompts

Dyne Therapeutics, Inc. (ticker DYN), listed in United States.

ETFs Holding Dyne Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
TMED 2.03% 21,069 $ 467.942K Jun 30, 2026
JDOC 0.48% 2,968 $ 47.547K Nov 17, 2026
SCDS 0.32% 1,846 $ 29.573K Nov 17, 2026
ESSC 0.23% 3,298 $ 83.044K Jul 31, 2026
TMSL 0.12% 146,334 $ 3.25M Jun 30, 2026
TCAF 0.11% 711,964 $ 11.89M Nov 17, 2026
FSEG 0.10% 264 $ 5,863.44 Jun 30, 2026
RESM 0.09% 154 $ 3,420.34 Jun 30, 2026
VFMO 0.04% 32,943 $ 837.74K Aug 31, 2026
DFAS 0.04% 842,352 $ 14.328M Nov 12, 2026
FESM 0.03% 73,565 $ 1.634M Jun 30, 2026
MSSM 0.01% 2,974 $ 75.629K Aug 31, 2026
DFAC 0.01% 378,418 $ 6.437M Nov 12, 2026
DFAU 0.01% 41,847 $ 711.817K Nov 12, 2026
DCOR 0.01% 143,639 $ 2.443M Nov 12, 2026
DFUS 0.00% 43,779 $ 744.681K Nov 12, 2026
DXUV 0.00% 711 $ 12.094K Nov 12, 2026